ReCode Therapeutics
https://recodetx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ReCode Therapeutics
Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds
Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.
Finance Watch: October Begins With A VC Mega-Round For Newly Named Iambic
Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.
Finance Watch: ReCode’s Series B Mega-Round Grows Again With $50m Boost
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice